PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2020

Sandusky, Ohio--(Newsfile Corp. - January 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2020.

Metadata

Provider:

Newsfile

Retrieved on:

Monday, January 11, 2021

Information

Tags:

Entheogens, Euphoriants, Medicinal plants, Herbs, Psychoactive drugs, Cannabis, Cannabis smoking, OTC Markets Group, COPD: Journal of Chronic Obstructive Pulmonary Disease, Hemp, Plants, Branches of biology

Geotags:

Sandusky, Ohio

Organisation:

PAO GROUP, INC.

Summary

Key Points:

Sandusky, Ohio--(Newsfile Corp. - January 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2020.
In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Sandusky, Ohio--(Newsfile Corp. - January 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced an update covering the company's 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14^th, 2020.

In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) and RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

The global asthma and COPD market is expected to reach $50 billion by 2022.

PAOG recently announced a key contract with a Contract Research Organization (CRO) to advance the company's RespRx formula through the process to becoming an approved pharmaceutical treatment.

The company also recently confirmed that the company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020.

Look for the update this Thursday to learn more.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71751